Drugs / MenAfriVac™
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT03746665 | Dec 2018 → Oct 2020 | meningitis, meningococcal infection | London School of Hygiene and Tropical Medicine | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01119482 | May 2010 → May 2012 | meningitis | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MenAfriVac | “Once final eligibility has been confirmed by a study clinician on the day, expectant mothers will be administered a single intramuscular dose of MenAfriVac™.” NCT03746665 ↗ |
| Modality | Vaccine | “meningococcal serogroup A conjugate vaccine” NCT01119482 ↗ |
| Route | Intramuscular | “single intramuscular injection” NCT01119482 ↗ |